Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

Michael S. van der Veer, Michel de Weers, Berris van Kessel, Joost M. Bakker, Shulamiet Wittebol, Paul W.H.I. Parren, Henk M. Lokhorst, and Tuna Mutis

1Dept. of Clinical Chemistry and Hematology, University Medical Center Utrecht, Utrecht; 2Genmab, Utrecht; 3Dept. of Internal Medicine, Meander Medical Center, Amersfoort, and 4Dept. of Hematology, University Medical Center Utrecht, Utrecht, Netherlands


Online Supplementary Figure S1. DARA+LEN does not influence the survival of normal CD38+CD14+ monocytes and CD38+CD16+ NK cells in peripheral blood. PBMC from 4 healthy individuals were either left untreated or incubated with DARA (10 μg/mL), LEN (3μm) or LEN+DARA. After 72 h the percentage of surviving CD38+CD14+ and CD38+CD16+ cells, which all together comprise over 90% of the CD38+ cells in PBMCs, were determined by FACS analysis as described in the Design and Methods section. To eliminate any hindrance with DARA, cells were labeled with a PE-labeled anti CD38 antibody recognizing a different epitope than DARA. Results represent the mean values. Error bars represent the SEM.

Online Supplementary Figure S2. ADCC effector cells are CD3- cells. PBMC from a healthy donor were MACS separated into a CD3+ and CD3- population. The CD3- population showed lysis after 4 h. As previously described by others this fast acting population consists of NK cells and monocytes.